Ameriprise Financial Inc Beam Therapeutics Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $26,885 - $41,380	1,267 Added 0.55%	230,172 $5.39 Million
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $870,131 - $1.67 Million	-37,090 Reduced 13.94%	228,905 $7.56 Million
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $4.42 Million - $7.69 Million	249,865 Added 1549.07%	265,995 $7.24 Million
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $153,177 - $216,086	6,657 Added 70.27%	16,130 $387,000
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $277,748 - $340,933	9,473 New	9,473 $302,000
Q4 2022 Feb 14, 2023	SELL	$36.73 - $51.6 $1.81 Million - $2.54 Million	-49,291 Reduced 87.04%	7,337 $286,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $2.25 Million - $3.98 Million	56,628 New	56,628 $2.7 Million
Q2 2022 Aug 15, 2022	SELL	$29.86 - $62.36 $290,597 - $606,887	-9,732 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $387,769 - $592,948	7,217 Added 286.96%	9,732 $558,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $171,070 - $249,135	2,515 New	2,515 $200,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.